Related Experiment Video
Updated: May 21, 2026
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co-Infected With HIV
Aung Pyae Phyo1,2, Richard M Hoglund2,3, Makoto Saito2,4
1Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Shoklo Malaria Research Unit, Mahidol University, Mae Ramat, Tak, Thailand.
Background:
HIV co-infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first-line anti-TB drugs and clinical outcomes in patients with and without HIV co-infection.
Methods:
In this prospective observational study, 61 adults with sputum-positive pulmonary TB, either confirmed by microscopy or GeneXpert, were enrolled, including 24 with HIV co-infection and 37 without. All HIV-positive participants were antiretroviral-naïve at enrolment. Standard anti-TB therapy was given, and PK assessments were conducted on Day 1 and Week 6. Efavirenz-based antiretroviral therapy (ART) began at a median of Day 21. Clinical outcomes, sputum conversion, and adverse events were monitored.
Results:
At baseline, patients with HIV co-infection had reduced clearance of isoniazid and ethambutol, reflected by slower elimination rates. These differences resolved by Week 6 and were not significantly impacted by ART initiation. Logistic regression showed that HIV-positive status (OR = 14.25, 95% CI: 1.22-166.37, p = 0.03), and higher baseline sputum bacillary load (OR = 3.92, 95% CI: 1.5-10.5, p = 0.006) were independently associated with delayed sputum conversion beyond 8 weeks. Baseline CRP showed an inverse association after adjustment, but this did not reach statistical significance (OR = 0.98, 95% CI: 0.96-1.00, p = 0.06).
Conclusion:
HIV co-infection was associated with altered early PK of isoniazid and ethambutol although these differences were less apparent by Week 6. HIV-positive status and higher baseline sputum bacillary load were associated with delayed sputum conversion. Although some pharmacokinetic differences were statistically significant, their clinical relevance remains uncertain, and the current data do not support dose adjustment. These findings suggest early pharmacokinetic variability in TB-HIV co-infected patients and support further investigation in adequately powered exposure-response studies.
Trial Registration:
ClinicalTrials.gov: NCT02457208.
Related Concept Videos
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment